In a groundbreaking partnership, QuEra Computing, a leader in neutral-atom quantum computing, has teamed up with Quantum Intelligence Corp., a South Korean pioneer in AI-driven drug development. This collaboration aims to revolutionize the way drugs are discovered and developed by harnessing the extraordinary computing power of QuEra's cutting-edge neutral atom-type quantum computers. The partnership will integrate QuEra's technology with QIC's QUEST platform, which uses algorithms to predict how a drug will behave in the body, evaluating its effectiveness and safety. Dr. Hwanho Choi, CEO of QIC, believes this integration will enable accurate detection of potential side effects at early stages of drug development, reducing risks and improving treatment safety. Yuval Boger, Chief Commercial Officer of QuEra Computing, sees this partnership as a significant step in applying quantum computing to drug discovery, hoping to achieve faster and more accurate development of new medicines.
↧